We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App





LumiraDx Demonstrates Transformative Tests and Technologies

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is presenting its innovative, next-generation point-of-care diagnostics Platform and broad test menu alongside its Fast Lab Solutions at MEDICA 2023.

The LumiraDx Platform is an innovative, next-generation point-of-care system that combines a small, portable instrument, advanced low-cost test strip, and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point-of-care clinical performance while being simple and easy to use. LumiraDx offers various tests that run on the highly portable LumiraDx Platform, such as the LumiraDx NT-proBNP test which is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available. The rapid microfluidic immunofluorescence assay can aid in the diagnosis of congestive heart failure (CHF).

LumiraDx also offers its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test that runs on the portable LumiraDx platform which weighs just over a kilogram. The point of care CRP test can be used in multiple clinical settings to help reduce unnecessary antibiotic prescribing that leads to antimicrobial resistance. From a tiny sample of finger-prick blood, the CRP test gives results within four minutes. Additionally, LumiraDx’s HbA1c test for professional use across multiple care settings is used alongside the LumiraDx Platform. The test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening and identifying patients who may be at risk for developing diabetes. Providing results in less than seven minutes from sample application, the test allows improved efficiency and convenience with on-the-spot diabetes screening and monitoring at the patient’s side.

At MEDICA 2023, LumiraDx is highlighting its LumiraDx INR Test which is an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. Another test that supports confident decisions at the point of care with the LumiraDx Platform is the LumiraDx D-Dimer Test which is a rapid microfluidic immunoassay for quantitative determination of D-Dimer. It is the only D-Dimer Test providing fast, accurate, quantitative results in just 6 minutes from a fingerstick blood sample.

Related Links:
LumiraDx 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.